Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors

HONG KONG, Oct. 22, 2021 /PRNewswire/ -- Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently develo...

Full "IntellAsia: Resources" article